Answers are grounded in this paper and cite their sources.
Milk-alkali syndrome or its up-to-date definition ‘calcium-alkali syndrome’ (CAS),1 is characterized by the triad of hypercalcemia, metabolic alkalosis and various degrees of renal failure, due to the intake of variable amounts of calcium and absorbable alkali. Its initial description dates back to the early 20th century when ‘alkali powders’ became a popular therapy for peptic ulcer disease.2 In 1923, two researchers from the Mayo Clinic, Leo Hardt and Andrew Rivers,3 described the adverse effects of this treatment, and in the three following decades communications about toxicity of Sippy's protocol were frequent.4 CAS has become a rare cause of hypercalcemia (<1% of cases) since proton pump inhibitor therapy was introduced in the 1990s.5,6 Nevertheless, it remains the third most common cause of hypercalcemia and the second most frequent cause of severe hypercalcemia among inpatients.5 The main reason for the rise of incidences of CAS is the increase of calcium carbonate use for prophylaxis and treatment of osteoporosis in post-menopausal women.
No takes yet. Share an insight, caveat, or question.
Fernández et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: